SHYIELD™ Releases Statement on the Efficacy Against the 2019 Novel Coronavirus

Published: February 7, 2020

SHYIELD™ Releases Statement on the Efficacy Against the 2019 Novel Coronavirus

Due to the ongoing novel coronavirus (2019-nCoV) outbreak in several countries around the world, Public Health agencies are implementing strategies to prevent the spread of the virus.

In cases of emerging viral pathogens such as 2019-nCoV, Health Canada’s Broad Spectrum Virucide claim requirement may be used to determine expected efficacy of a disinfectant against the virus. This guidance utilizes an organism hierarchy to identify effective products for use with emerging pathogens and to permit registrants to make statements against such pathogens. In accordance with these guidelines, the SHYIELD™ line of disinfectants can be utilized against 2019-nCoV when used following the directions for use against Poliovirus type 1 on hard, non-porous surfaces. For further information, please review our formal press release below:

As the Novel Coronavirus is an emerging pathogen, neither the EPA nor Health Canada have an approved test method for determining or allowing disinfectant efficacy product label claims. In cases of emerging viral pathogens such as 2019-nCoV, Health Canada’s Broad Spectrum Virucide claim requirement may be used to determine expected efficacy of a disinfectant against the virus. This guidance is based on a hierarchy of susceptibility of viruses to disinfectants, recognizing that a product with efficacy against non-enveloped viruses will also be effective against enveloped viruses, which are much more readily inactivated. 

In accordance with the Guidance Document – Safety and Efficacy Requirements for Hard Surface Disinfectant Drugs, Health Canada considers that a registered disinfectant with submitted efficacy data against any of Poliovirus type 1, Chat strain, Human adenovirus type 5, Bovine parvovirus or Canine parvovirus is a broad-spectrum virucide, and is therefore expected to inactivate other enveloped and non- enveloped viruses. Coronaviruses are enveloped viruses, and would be expected to be readily inactivated by any Health Canada-registered broad-spectrum virucide. 

The SHYIELD(TM) line of disinfectants (concentrate, ready-to-use and premoistened wipes) have broad- spectrum virucidal efficacy, as well as demonstrated effectiveness against viruses similar to 2019-nCoV on hard, non-porous surfaces. Therefore, the SHYIELD(TM) line of disinfectants can be used against 2019-nCoV when used in accordance with the directions for use against Poliovirus type 1 on hard, non-porous surfaces. Refer to the Public Health Agency of Canada’s website at https://www.canada.ca/en/public-health.html for additional information. 

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at nkenny@virox.com

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article